Search results
-
ASCO 2025 – Dizal goes after the BTK leaders
… early but similarly inconclusive results in lymphoma at ASH 2023 . DZD8586 is also now in a phase 3 study in …
- 06/05/2025 - 16:57 -
Ono takes on Takeda in polycythemia vera
… Perseus Proteomics Anti-TfR1 MAb Ph1 Data at ASH 2023 MWTX-003 Disc Medicine/ Mabwell …
- 03/17/2025 - 15:14 -
Son of Darzalex hits the skids
… – echoing concerns around early data presented at ASH 2023 . During the conference call Genmab execs …
- 03/12/2025 - 10:45 -
The month ahead: March's upcoming events
… to be more potent; however, positive uncontrolled data at ASH 2023 came with a 50% discontinuation rate due to adverse …
- 03/21/2025 - 08:31 -
ASH 2024 – full steam ahead for arlo-cel
… CR rate ASH 2022 19 90% 47% ASH 2023 73 88% 45% 23 at ph2 dose* 91% …
- 12/10/2024 - 14:46 -
ASH 2024 preview – more challenges to the BTK order
… Nurix and BeiGene's BTK degraders, which went toe to toe at ASH 2023 and then put up impressive data at this year's …
- 11/14/2024 - 15:27 -
ASH 2024 preview – multiple myeloma in focus
… project BMS-986393. This reported first phase 1 results at ASH 2023, showing an 88% response rate among 73 patients, …
- 11/13/2024 - 12:23 -
New Roche/Poseida project isn’t P-BCMACD19-ALLO1
… of which yielded confounding multiple myeloma data at ASH 2023 ; the dataset now stands at 72 patients, with an …
- 10/22/2024 - 13:43 -
Xencor “still committed” to oncology
… acute leukaemia & T-cell lymphoblastic leukaemia Data at ASH 2023, 2/12 CRs; no longer listed in pipeline …
- 09/10/2024 - 08:01 -
Front-line setting next for axatilimab
… Ph2 Agave-201, monotherapy Approved in US, data at ASH 2023 First line Ph2 Jakafi combo …
- 08/15/2024 - 13:37
